Editorial
From tradition to transformation: evolving paradigms in surgical lung cancer treatment
Translational Lung Cancer Research
2025;
14
(9)
:3280-3283
.
(30 September 2025)
MicroRNA expression in pleural fluid as a diagnostic biomarker of malignant pleural effusion: promise, pragmatism, and the path forward
Translational Lung Cancer Research
2025;
14
(9)
:3284-3291
.
(30 September 2025)
Nucleic acids in pleural fluid for the etiological diagnosis of pleural effusion
Translational Lung Cancer Research
2025;
14
(9)
:3292-3298
.
(30 September 2025)
Expert Consensus
Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement
Translational Lung Cancer Research
2025;
14
(9)
:3299-3322
.
(30 September 2025)
Original Article
Integrating deep learning and radiomics in the differentiation of major histological subtypes of invasive non-mucinous lung adenocarcinoma using positron emission tomography and computed tomography
Translational Lung Cancer Research
2025;
14
(9)
:3323-3336
.
(30 September 2025)
Outcomes and prognostic insights in primary tracheal cancer: a multicenter retrospective study
Translational Lung Cancer Research
2025;
14
(9)
:3337-3348
.
(30 September 2025)
Density and maturity ratio of tertiary lymphoid structures in stage II–III non-small cell lung cancer predict postoperative recurrence risk
Translational Lung Cancer Research
2025;
14
(9)
:3349-3362
.
(30 September 2025)
Survival benefits in non-small cell lung cancer during the immune checkpoint inhibitor era: integrating lymph node burden for prognostic precision
Translational Lung Cancer Research
2025;
14
(9)
:3363-3377
.
(30 September 2025)
Efficacy and safety of perioperative, adjuvant and neoadjuvant chemoimmunotherapy stratified by clinical stage and PD-L1 expression in resectable non-small cell lung cancer: a systematic review and network meta-analysis
Translational Lung Cancer Research
2025;
14
(9)
:3378-3395
.
(30 September 2025)
Efficacy and safety of neoadjuvant chemotherapy with or without PD-L1/PD-1 inhibitors in surgically limited-stage small-cell lung cancer
Translational Lung Cancer Research
2025;
14
(9)
:3396-3409
.
(30 September 2025)
Actionable mutations and targeted therapy in non-small cell lung cancer among Latin American and Hispanic patients: a systematic literature review of prognosis and meta-analysis
Translational Lung Cancer Research
2025;
14
(9)
:3410-3429
.
(30 September 2025)
Potential efficacy of anti-angiogenic therapy combined with immunotherapy for advanced SMARCA4-deficient thoracic tumor: a retrospective study
Translational Lung Cancer Research
2025;
14
(9)
:3430-3443
.
(30 September 2025)
An effective and affordable blood test for lung cancer early detection using four protein markers and artificial intelligence
Translational Lung Cancer Research
2025;
14
(9)
:3444-3456
.
(30 September 2025)
Immune checkpoint inhibitors combined with chemotherapy as first-line treatment may improve clinical outcomes in advanced non-small cell lung cancer with bone metastases
Translational Lung Cancer Research
2025;
14
(9)
:3457-3467
.
(30 September 2025)
Tumor rim-specific computed tomography radiomics improves prediction of pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(9)
:3468-3485
.
(30 September 2025)
Effect of neoadjuvant vs. adjuvant systemic therapy on survival in patients with surgical resected limited stage small-cell lung cancer: a real-world retrospective cohort study from SEER database
Translational Lung Cancer Research
2025;
14
(9)
:3486-3500
.
(30 September 2025)
Comparative survival outcomes between EGFR-wildtype and EGFR-mutant lung adenocarcinoma following neoadjuvant chemoimmunotherapy: a retrospective cohort study from national cancer center in China
Translational Lung Cancer Research
2025;
14
(9)
:3501-3517
.
(30 September 2025)
Outcomes of radial probe endobronchial ultrasound-guided transbronchial lung cryobiopsy using guide sheath and the target fixing technique
Translational Lung Cancer Research
2025;
14
(9)
:3518-3528
.
(30 September 2025)
Comparative study of bronchoscopic and CT-guided percutaneous microwave ablation for inoperable non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(9)
:3529-3541
.
(30 September 2025)
Adjuvant chemotherapy before osimertinib in EGFR-mutated stage IB lung adenocarcinoma: a clinical dilemma
Translational Lung Cancer Research
2025;
14
(9)
:3542-3552
.
(30 September 2025)
Multi-omics and Mendelian randomization identify S1PR5 as a causal protective gene and NK cell-mediated prognostic biomarker in lung adenocarcinoma
Translational Lung Cancer Research
2025;
14
(9)
:3553-3576
.
(30 September 2025)
Performance comparison of four published lung cancer prediction models applied to a cohort from the National Lung Screening Trial
Translational Lung Cancer Research
2025;
14
(9)
:3577-3588
.
(30 September 2025)
Prognostic factors affecting mortality in elderly, low body mass index, and poor performance status groups with lung cancer: analysis of the 2016 Korean Association of Lung Cancer Registry (KALC-R) database
Translational Lung Cancer Research
2025;
14
(9)
:3589-3606
.
(30 September 2025)
Combination of racotumomab immunotherapy with programmed death-1 blockade in a preclinical model of non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(9)
:3607-3622
.
(30 September 2025)
Monocyte-Platelet-Hemoglobin-Hematocrit score and the role of hematological parameters in predicting treatment response to immune checkpoint inhibitors and survival outcomes in non-small cell lung cancer patients—a retrospective study
Translational Lung Cancer Research
2025;
14
(9)
:3623-3635
.
(30 September 2025)
Evaluation of ultrasonic energy for sealing 5–7 mm blood vessels in thoracoscopic surgery: a noninferiority randomized controlled trial
Translational Lung Cancer Research
2025;
14
(9)
:3636-3644
.
(30 September 2025)
Biomarkers for non-small cell lung cancer risk using multi-omics approaches: a nested case-control study
Translational Lung Cancer Research
2025;
14
(9)
:3645-3658
.
(30 September 2025)
The pathogenic mutations in smokers with non-small cell lung cancer: a next-generation sequencing study
Translational Lung Cancer Research
2025;
14
(9)
:3659-3672
.
(30 September 2025)
Expression of YAP1 delineates distinct subtypes of pulmonary large cell neuroendocrine carcinoma with divergent therapeutic implications
Translational Lung Cancer Research
2025;
14
(9)
:3673-3689
.
(30 September 2025)
Radiomic phenotypes of oligometastatic non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(9)
:3690-3702
.
(30 September 2025)
Imaging biomarkers related to tumor-associated macrophage in immunotherapy treatment planning for non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(9)
:3703-3719
.
(30 September 2025)
Osimertinib resistance-based immune prognostic related gene signature in EGFR mutant lung adenocarcinoma, in which PSMD11 promotes tumor progression
Translational Lung Cancer Research
2025;
14
(9)
:3720-3739
.
(30 September 2025)
Myelopreservation effect of trilaciclib in extensive-stage small cell lung cancer (ES-SCLC): a systematic review and meta-analysis with trial sequential analysis of randomized clinical trials
Translational Lung Cancer Research
2025;
14
(9)
:3740-3752
.
(30 September 2025)
The difference in tumor immune microenvironment and IFN-γ response between solid and non-solid adenocarcinoma
Translational Lung Cancer Research
2025;
14
(9)
:3753-3768
.
(30 September 2025)
Synergistic camrelizumab therapy inhibits P53-mutant osimertinib-resistant solid lung adenocarcinoma via the TGF-β signaling pathway
Translational Lung Cancer Research
2025;
14
(9)
:3769-3795
.
(30 September 2025)
C1orf116 inhibits acquired resistance to EGFR inhibitors in EGFR mutant lung adenocarcinoma by suppressing the ATM/ATR pathways
Translational Lung Cancer Research
2025;
14
(9)
:3796-3810
.
(30 September 2025)
Real-world insights into atezolizumab plus bevacizumab, carboplatin, and paclitaxel for advanced non-squamous non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(9)
:3811-3823
.
(30 September 2025)
Molecular and clonal evolution of primary lesions vs. brain metastasis in EGFR-mutated NSCLC: a retrospective cohort study
Translational Lung Cancer Research
2025;
14
(9)
:3824-3835
.
(30 September 2025)
Metabolic phenotype and gender may predict treatment outcomes of atezolizumab in extensive-stage small cell lung cancer
Translational Lung Cancer Research
2025;
14
(9)
:3836-3846
.
(30 September 2025)
Induction chemoimmunotherapy and surgery for unresectable stage III non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(9)
:3847-3860
.
(30 September 2025)
Real-world outcomes and association between immune-related adverse events and therapeutic efficacy of nivolumab plus ipilimumab in elderly patients (≥75 years) with advanced non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(9)
:3861-3871
.
(30 September 2025)
Patients’ survival outcomes in clinical stage IA lung adenocarcinoma not affected by preoperative staging brain magnetic resonance imaging
Translational Lung Cancer Research
2025;
14
(9)
:3872-3885
.
(30 September 2025)
Multi-institutional development and validation of habitat imaging for predicting outcomes of first-line immunotherapy in advanced non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(9)
:3886-3899
.
(30 September 2025)
Prognostic impact of dose to circulating blood cells in non-small cell lung cancer patients after chemoradiotherapy
Translational Lung Cancer Research
2025;
14
(9)
:3900-3912
.
(30 September 2025)
PD-L1 expression as a prognostic factor for postoperative outcomes in pleural mesothelioma
Translational Lung Cancer Research
2025;
14
(9)
:3913-3923
.
(30 September 2025)
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(9)
:3924-3938
.
(30 September 2025)
Prognostic biomarkers for extensive-stage small cell lung cancer receiving amrubicin following failure of chemoimmunotherapy: a retrospective cohort study
Translational Lung Cancer Research
2025;
14
(9)
:3939-3950
.
(30 September 2025)
Genome-scale metabolic modeling and machine learning unravel metabolic reprogramming and mast cell role in lung cancer: a multi-level analysis
Translational Lung Cancer Research
2025;
14
(9)
:3951-3974
.
(30 September 2025)
Tumor immune microenvironment analysis in different pathologic responses to neoadjuvant immunotherapy combined with chemotherapy in non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(9)
:3975-3987
.
(30 September 2025)
TTF-1 and p40 co-expression defines a distinct subtype of non-small cell lung cancer with frequent TP53 mutations and FGFR pathway dysregulation
Translational Lung Cancer Research
2025;
14
(9)
:3988-4001
.
(30 September 2025)
Single-cell and spatial analysis reveals macrophage-T cell crosstalk in non-small cell lung cancer immunosuppression
Translational Lung Cancer Research
2025;
14
(9)
:4002-4020
.
(30 September 2025)
Risk of conversion and severe postoperative complications in older patients with non-small cell lung cancer and a history of COVID-19: a population-based study
Translational Lung Cancer Research
2025;
14
(9)
:4021-4036
.
(30 September 2025)
Pre-screening value of serum albumin and the glucose-lymphocyte ratio as the “transport-activation” effectors of immune checkpoint inhibitors in small cell lung cancer
Translational Lung Cancer Research
2025;
14
(9)
:4037-4050
.
(30 September 2025)
Case Series
A case series of nonintubated robotic-assisted bronchoscopy: a feasible alternative to intubated techniques
Translational Lung Cancer Research
2025;
14
(9)
:4051-4056
.
(30 September 2025)
Study Protocol
Multimodal prehabilitation to prevent loss of cardiorespiratory fitness in patients with locally advanced lung cancer undergoing chemoimmunotherapy: protocol for a non-randomized multicentre study
Translational Lung Cancer Research
2025;
14
(9)
:4057-4067
.
(30 September 2025)
Review Article
Artificial intelligence in medical education for pulmonary nodule management: a narrative review
Translational Lung Cancer Research
2025;
14
(9)
:4068-4077
.
(30 September 2025)
The evolving role of wedge resection in early-stage non-small cell lung cancer: a literature review
Translational Lung Cancer Research
2025;
14
(9)
:4078-4094
.
(30 September 2025)
Metabolite biomarkers in lung cancer: unlocking the potential of body fluid analysis for early detection and prognosis—a narrative review
Translational Lung Cancer Research
2025;
14
(9)
:4095-4111
.
(30 September 2025)
Decoding the tumor immune microenvironment in lung squamous cell carcinoma: characteristics, regulatory mechanisms, and future directions in immunotherapy
Translational Lung Cancer Research
2025;
14
(9)
:4112-4130
.
(30 September 2025)
Case Report
Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) by osimertinib and continued treatment with dose reduction for postoperative recurrence of lung adenocarcinoma: a case report
Translational Lung Cancer Research
2025;
14
(9)
:4131-4136
.
(30 September 2025)
First case report of immune checkpoint inhibitor-related pneumonitis triggered by bispecific antibody (anti-PD-L1 and anti-CTLA-4) in a patient with non-small cell lung cancer: case report
Translational Lung Cancer Research
2025;
14
(9)
:4137-4142
.
(30 September 2025)
Pseudoprogression of pleural effusion in lung cancer treated with immunotherapy: a case report
Translational Lung Cancer Research
2025;
14
(9)
:4143-4148
.
(30 September 2025)
Editorial Commentary
Tackling a caveat of the FLAURA trial and building solid evidence for frail patients in thoracic oncology
Translational Lung Cancer Research
2025;
14
(9)
:4149-4152
.
(30 September 2025)
Refining maintenance strategies for metastatic nonsquamous non-small cell lung cancer: insights from the KEYLYNK-006 study
Translational Lung Cancer Research
2025;
14
(9)
:4153-4158
.
(30 September 2025)
Early checkpoint inhibition before chemoradiation: is the strategy ready for stage III non-small cell lung cancer?
Translational Lung Cancer Research
2025;
14
(9)
:4159-4164
.
(30 September 2025)
Sacituzumab govitecan: another emerging treatment option for patients with relapsed small cell lung cancer
Translational Lung Cancer Research
2025;
14
(9)
:4165-4169
.
(30 September 2025)
Utility of ctDNA-molecular residual disease in predicting minimal residual disease in non-small cell lung cancer patients after radical resection
Translational Lung Cancer Research
2025;
14
(9)
:4170-4174
.
(30 September 2025)
NY-ESO-1 targeting in non-small cell lung cancer: promise and challenges of letetresgene autoleucel
Translational Lung Cancer Research
2025;
14
(9)
:4175-4179
.
(30 September 2025)
